HQL
Tekla Life Sciences Investors
NYSE · Financial Services · Asset Management · US
$20.64
−0.34%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- —
Trailing multiples
Trailing twelve months
- P/E TTM
- 3.26x
- PEG TTM
- —
- Price / book
- 1.06x
- Price / sales
- 7.47x
- Price / cash flow
- -256.83x
Enterprise value
- Enterprise value
- $595.1M
- EV / sales
- 7.46x
- EV / EBITDA
- 3.20x
- EV / EBIT
- 3.98x
- Market cap
- $595.9M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Mar 1, 2026